Identifying Bronchiectasis: Key Clinical Presentations to Consider

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.

These data from the Environmental Protection Agency were presented at the Society for Risk Analysis annual meeting.

Courtney Blair, MD, discusses how COVID-19 has impacted patients with allergies and other respiratory conditions.

A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on vaccines for flu and respiratory syncytial virus (RSV).

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.